Pillstats
Rx only · Capsule · Oral

Diroximel Fumarate

Brands: Vumerity · Diroximel Fumarate

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCL04AX09
RxCUI (US)2261783
US makers1 labelers
Packages2
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

1.1K2.2K3.3K4.3K2025 Q12025 Q22025 Q32025 Q42026 Q1
3.1K
Rx · 2026 Q1
405K
Units dispensed
-14%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Biogen Inc.unknown2SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Dec 9, 2020
    RECALLRecall (Class II): Vumerity (diroximel fumarate) delayed-release capsule, 231 mg, packaged in a) 106-count bottle, b)120-count bottle, Rx…

    Failed dissolution specifications: out-of-specification test results observed during the buffer stage dissolution testing. — Recalling firm: Biogen MA Inc. — USA Nationwide